06/01/2026
Tirzepatide vs. Retatrutide — what research actually shows. And which one might surprise you.
These are two of the most researched compounds in metabolic health right now. But the conversation around them is full of myths, hype, and missing context.
So let’s talk about what the research actually says.
Tirzepatide is a dual GLP-1 and GIP receptor agonist. FDA approved. Extensive clinical trial data. The SURPASS trials showed significant outcomes across metabolic health markers.
Retatrutide is a triple agonist — GLP-1, GIP, and glucagon. Currently in Phase 3 clinical trials. Not yet FDA approved. The TRIUMPH-1 Phase 2 data produced outcomes that made the research community pay very close attention.
The difference that matters: that third receptor.
Glucagon signaling may support increased energy expenditure — meaning the body burns more, not just takes in less. That’s a meaningfully different metabolic mechanism than dual agonism alone.
But more receptors doesn’t automatically mean better results for everyone. Side effect profiles differ. Individual response varies enormously. And neither compound works optimally without the right foundation in place.
Protein. Resistance training. Gut health. Nutrient status. Titration pace.
The research is consistent on this: the compound is only part of the outcome.
Swipe through for the full breakdown — mechanisms, myths, side effect profiles, and what research suggests about which one may be right for different goals.
DM me “GUIDE” and I’ll send you the free optimization guide 📖
⚠️ Educational purposes only. Both compounds require physician oversight. Retatrutide is not FDA approved and is currently in clinical trials. Individual results vary. This is not medical advice.